Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025, regarding the Company's recently closed non-brokered private placement.
The previous release incorrectly stated that the Units were issued at a price of $0.10 per Unit. The correct issue price was $0.05 per Unit.
Accordingly, the Company issued 2,000,000 units (each, a "Unit") at a price of $0.05 per Unit, for total gross proceeds of $100,000. Each Unit consists of one common share of the Company (a "Share") and one transferable common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire one additional Share at a price of $0.10 per Share for a period of two (2) years from the date of closing, expiring on September 4, 2027 (the "Expiry Date").
All other terms of the private placement remain unchanged.
About Genix
Genix Pharmaceuticals Corporation is a highly innovative Canadian ophthalmic drugs company. The Company focusses on the research, development, manufacture, licensing and sales of novel and innovative prescription and OTC ophthalmological products which meet the growing needs of consumers worldwide and especially the aging baby boomers. The Company has several products awaiting Health Canada approval.
On Behalf of the Board of Directors,
Mr. Mahmoud S. Aziz, President, Director
Genix Pharmaceuticals Corporation
www.genixpharm.com
For more information regarding Genix Pharmaceuticals Corporation, please contact:
Kevin Bottomley, Director
Tel: +1.604.609.6199
kbottomley@genixpharm.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269553
SOURCE: Genix Pharmaceuticals Corp.
